The disease primarily targets the central nervous system, especially the white matter regions responsible for coordinating movement, balance, and motor control. As myelin breaks down, nerve signals become slow, weak, or completely interrupted. This results in progressive neurological dysfunction that worsens over time.
Clinical signs of LEMP typically appear in young to middle-aged dogs, although onset may vary depending on breed and genetic background. Early symptoms are often subtle and may include mild weakness, stiffness, or slight difficulty coordinating movements. As the condition progresses, dogs develop more noticeable neurological deficits such as ataxia (loss of coordination), hind limb weakness, and an abnormal gait.
Affected dogs may begin to drag their hind limbs, stumble frequently, or show reduced ability to maintain balance. Muscle wasting (atrophy) can occur over time due to reduced nerve stimulation. In more advanced stages, dogs may experience severe mobility impairment, difficulty standing or walking, and progressive loss of voluntary motor control.
Unlike some inflammatory neurological diseases, LEMP is non-inflammatory and degenerative, meaning there is no immune attack or infection involved. Instead, the disorder is caused by structural breakdown of myelin, which leads to a steady decline in nervous system function. The progression rate can vary, but the condition is generally irreversible and gradually worsens.
The LEMP DNA Health Test is designed to detect the specific genetic mutation associated with Leukoencephalomyelopathy. The test is simple, safe, and non-invasive, typically performed using a cheek swab or blood sample. The collected DNA is analyzed in a specialized laboratory to determine whether the dog carries zero, one, or two copies of the mutation. Since DNA does not change over a dog’s lifetime, testing can be performed at any age, including before clinical signs appear.
Results are generally reported in three categories:
- Clear (Normal): The dog does not carry the LEMP mutation and is not expected to develop or pass on the disease.
- Carrier: The dog carries one copy of the mutation but is typically unaffected. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and is expected to develop progressive neurological signs associated with LEMP.
Genetic testing for LEMP is highly valuable for breeders, veterinarians, and dog owners. Breeders can use test results to avoid carrier-to-carrier matings, helping reduce the incidence of this debilitating neurological disorder in future generations while maintaining healthy genetic diversity.
For dog owners, knowing a dog’s genetic status allows for early awareness and supportive care planning. While there is currently no cure for LEMP, supportive management such as physiotherapy, mobility assistance, and environmental modifications can help maintain comfort and quality of life for affected dogs. Regular neurological evaluations are important for monitoring disease progression.
The Leukoencephalomyelopathy (LEMP) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine neurological health, and helps reduce the impact of this inherited white matter disorder in future generations.
